# Scemblix (asciminib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/asciminib

> The FDA approved Scemblix (asciminib), sponsored by NOVARTIS AG (NVS), on October 29, 2021.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Scemblix (asciminib) |
| Codes | ABL001 |
| Sponsor | NOVARTIS AG (NVS) https://sec-api.dev/companies/nvs/catalysts |
| Indications | Chronic Myelogenous Leukemia - Chronic Phase, [Philadelphia Chromosome-Positive Chronic Myeloid Leukemia](https://sec-api.dev/indications/philadelphia-chromosome-positive-chronic-myeloid-leukemia) |
| Modality | small_molecule |
| FDA designations | accelerated, priority review |

## Timeline

### October 29, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215358 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20211029, review_priority PRIORITY; sponsor_name NOVARTIS; product SCEMBLIX (ASCIMINIB HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215358%22
- openFDA Drugs@FDA: "NDA215358 ORIG-2 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20211029, review_priority PRIORITY; sponsor_name NOVARTIS; product SCEMBLIX (ASCIMINIB HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215358%22

### October 12, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215358 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20221012, review_priority PRIORITY; sponsor_name NOVARTIS; product SCEMBLIX (ASCIMINIB HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215358%22

### October 29, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215358 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20241029, review_priority PRIORITY; sponsor_name NOVARTIS; product SCEMBLIX (ASCIMINIB HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215358%22
- openFDA Drugs@FDA: "NDA215358 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20241029, review_priority PRIORITY; sponsor_name NOVARTIS; product SCEMBLIX (ASCIMINIB HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215358%22

### May 15, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05456191 (A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-05-27." https://clinicaltrials.gov/study/NCT05456191

### August 13, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Chronic Myelogenous Leukemia - Chronic Phase.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05384587 (Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-08-13 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05384587

### October 2, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215358 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20251002, review_priority STANDARD; sponsor_name NOVARTIS; product SCEMBLIX (ASCIMINIB HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215358%22

### November 25, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215358 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20251125, review_priority STANDARD; sponsor_name NOVARTIS; product SCEMBLIX (ASCIMINIB HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215358%22

### May 27, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05456191 (A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-05-27." https://clinicaltrials.gov/study/NCT05456191?tab=results

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/asciminib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Scemblix (asciminib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/asciminib

```bibtex
@misc{secapidev_pdufa_asciminib_20261116,
  title        = {Scemblix (asciminib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/asciminib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_asciminib_20261116","title":"Scemblix (asciminib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/asciminib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
